Eli Lilly Fair Value
0Q
The fair market value of 0Q1G.L stock is 385.25 CHF. Relative to the market price of 0 CHF Eli Lilly is overvalued by 47.4%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Eli Lilly Valuation
The fair value level of 385.25 CHF can be considered as an effective entry point for long-term investors to start investing in 0Q1G.L stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Market price:
0Q1G.L stock is overvalued
It means the current price may concern as a Risky Entry Point
Eli Lilly and Co Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
103.91
2
Median P/E over 5 years
49.13
3
Minimum P/E over 5 years
25.74
4
Earning per share (last 12 months)
8.81 USD
Maximum value
1
x
4
=
814.76 CHF
Fair value
2
x
4
=
385.25 CHF
Minimum value
3
x
4
=
201.84 CHF
Eli Lilly and Co price metrics
49.19
Annual return (geometric mean)
31.81
Risk (standard deviation) of returns
β
0.9
Beta (volatility compared to market)